An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor
Abstract Background. Molecular analysis has revealed four subtypes of pancreatic ductal adenocarcinoma (PDAC). One subtype identified for the presence of DNA damage repair deficiency can be targeted therapeutically with the poly (ADP‐ribose) polymerase (PARP) inhibitor olaparib. We performed a single-institution… Read More